The Sheppard Mullin Life Sciences Team decided to take a different approach to our year-end review. We surveyed and considered issues most important to our clients, asking the experts across the various specialties in our Life Sciences Practice the following question: What do life sciences companies need to keep top of mind in 2023?

Answers poured in. So many, in fact, that we needed to whittle down this publication. The pieces that remain, however, span the gamut – from the ability of manufacturers to offer drug cost-sharing subsidies to patients to the patchwork of privacy laws popping up across the country to repricing stock options in a bear market. Of course, no annual life sciences publication would be complete without an assessment of enforcement actions over the past year. Be sure to follow our blogs and client alerts throughout the year to see how these top-of-mind topics pan out.

Click here to read more.